Cancer and Metastasis Reviews

Papers
(The TQCC of Cancer and Metastasis Reviews is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-09-01 to 2025-09-01.)
ArticleCitations
Editorial Expression of Concern: Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer216
Immunotherapy for leptomeningeal disease from solid tumors: current clinical outcomes and future opportunities148
The impact of tumor microenvironment: unraveling the role of physical cues in breast cancer progression111
Clonal tracking in cancer and metastasis102
CAR T-cell therapy for B-cell lymphomas: outcomes and resistance mechanisms80
New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions78
The functions and modifications of tRNA-derived small RNAs in cancer biology77
Obesity and cancer70
Of vascular defense, hemostasis, cancer, and platelet biology: an evolutionary perspective67
Regulation of dormancy during tumor dissemination: the role of the ECM66
Targeting lipid metabolism in cancer: neuroblastoma52
The paradoxical role of inositol in cancer: a consequence of the metabolic state of a tumor50
Progression and metastasis of small cell lung carcinoma: the role of the PI3K/Akt/mTOR pathway and metabolic alterations49
CAR T-cell therapy to treat multiple myeloma: current state and future directions49
Immunotherapy for triple negative breast cancer: the end of the beginning or the beginning of the end?48
Natural killer cells in neuroblastoma: immunological insights and therapeutic perspectives48
The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer48
Cell-cell interactions mediating primary and metastatic breast cancer dormancy48
p73 isoforms meet evolution of metastasis46
KISS1 metastasis suppressor in tumor dormancy: a potential therapeutic target for metastatic cancers?41
TRIM-endous functional network of tripartite motif 29 (TRIM29) in cancer progression and beyond40
Healthcare disparities, screening, and molecular testing in the changing landscape of non–small cell lung cancer in the United States: a review40
A multidisciplinary perspective on the complex interactions between sleep, circadian, and metabolic disruption in cancer patients39
Preface37
Biography—Mathieu Boissan, Pharm.D., Ph.D36
Targeting microRNAs as a promising anti-cancer therapeutic strategy against traffic-related air pollution-mediated lung cancer36
LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance34
Neuropeptide Y in cancer—biological functions and potential clinical implications33
Role of Neuropilin-2-mediated signaling axis in cancer progression and therapy resistance31
Biographies31
Biographies31
How circulating tumor cluster biology contributes to the metastatic cascade: from invasion to dissemination and dormancy31
Short-chain fatty acids in cancer pathogenesis30
The multifaceted mechanisms of malignant glioblastoma progression and clinical implications30
Cross-talk between the microbiome and chronic inflammation in esophageal cancer: potential driver of oncogenesis29
The role of cancer cell bioenergetics in dormancy and drug resistance28
Immunomodulatory role of oncogenic alterations in non-small cell lung cancer: a review of implications for immunotherapy27
Systematic review of the receptor tyrosine kinase superfamily in neuroblastoma pathophysiology27
Clusterin: a marker and mediator of chemoresistance in colorectal cancer27
Helicobacter pylori–activated fibroblasts as a silent partner in gastric cancer development26
Tumor necrosis factor superfamily signaling: life and death in cancer26
The emerging roles of histone demethylases in cancers25
Clinical interventions to break the obesity and cancer link: a narrative review25
Tissue-engineered patient-derived osteosarcoma models dissecting tumour-bone interactions24
The tumor microenvironment in pancreatic ductal adenocarcinoma: current perspectives and future directions24
Vaping and tumor metastasis: current insights and progress24
Epigenetic reprogramming of T cells: unlocking new avenues for cancer immunotherapy24
Functional and clinical roles of stromal PDGF receptors in tumor biology23
Dormancy, stemness, and therapy resistance: interconnected players in cancer evolution23
Carcinoma of unknown primary (CUP): an update for histopathologists23
The role of mitochondria in tumor metastasis and advances in mitochondria-targeted cancer therapy23
Kenneth V. Honn, Ph.D. (1946–2023)23
Debris-stimulated tumor growth: a Pandora’s box?23
Heterogeneity and tumor evolution reflected in liquid biopsy in metastatic breast cancer patients: a review23
PRUNE1 and NME/NDPK family proteins influence energy metabolism and signaling in cancer metastases22
Inflammatory bowel disease and carcinogenesis22
OX40/OX40 ligand and its role in precision immune oncology22
Racial disparity in prostate cancer: an outlook in genetic and molecular landscape22
CTGF (CCN2): a multifaceted mediator in breast cancer progression and therapeutic targeting21
Oncogenic functions of the FOXC2 transcription factor: a hallmarks of cancer perspective21
New progress of tuberculosis scar carcinoma21
The strict regulation of HIF-1α by non-coding RNAs: new insight towards proliferation, metastasis, and therapeutic resistance strategies21
Ferroptosis: iron release mechanisms in the bioenergetic process21
UCP2 and pancreatic cancer: conscious uncoupling for therapeutic effect20
Biographies20
HOXA9 transcription factor is a double-edged sword: from development to cancer progression20
Multifaceted role of the DNA replication protein MCM10 in maintaining genome stability and its implication in human diseases19
Classification of anticancer drugs: an update with FDA- and EMA-approved drugs19
Current state-of-the-art on ganglioside-mediated immune modulation in the tumor microenvironment19
Is cancer an intelligent species?19
Understanding metabolic alterations and heterogeneity in cancer progression through validated immunodetection of key molecular components: a case of carbonic anhydrase IX19
0.053563833236694